Tenderwize
Retour à la recherche

Open-House Biologics Discount Contracts 2025-02 - Rituximab (Subcutaneous Injection Form)

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 185 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-02 - Rituximab (Darreichungsform zur subkutanen Injektion)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

25 / 100

Facteurs de risque

If the patent for Rituximab subcutaneous expires before the contract end (28.02.2027), the contract terminates automati...

No estimated volume or value is provided; actual sales may be low if many participants join.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Conclusion of pharmaceutical discount contracts for Rituximab (subcutaneous injection form) with all eligible pharmaceutical entrepreneurs under an open-house procedure.
Afficher le résumé complet

Open-house procedure for discount contracts (Rabattverträge) for the active substance Rituximab (subcutaneous injection form) under §130a Abs. 8 SGB V. The procedure is open to all eligible pharmaceutical entrepreneurs who can offer or intend to offer the product. Uniform conditions apply, no exclusivity, and contracts can be concluded at any time during the 24-month period from March 2025 to February 2027.

Risques

If the patent for Rituximab subcutaneous expires before the contract end (28.02.2027), the contract terminates automati...

No estimated volume or value is provided; actual sales may be low if many participants join.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs. 18 AMG.
  • Must have a valid marketing authorization for the product or be entitled to market it in own name.

Eligibility

  • Must declare eligibility and reliability via a self-declaration (Anlage 4 zum Vertrag).

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Contracts 2025-02 - Rituximab (Subcutaneous Injection Form)

Conclusion of discount contracts for Rituximab subcutaneous injection form with any eligible pharmaceutical entrepreneur.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 27, 2027

Détails de la procédure

Date de publication
23 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
50192-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3